Navidea Biopharmaceuticals (NEOP) Participates in Symposium Focused on Sentinel Lymph Node Biopsy at the International Symposium on Metastasis in Head and Neck Cancer
2/5/2013 7:17:22 AM
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it recently participated in a focused panel session at the 6th International Symposium on Metastasis in Head and Neck Cancer held in Marburg, Germany. Lymphoseek® (technetium Tc 99m tilmanocept) Injection and initial clinical experience data from one site participating in the Lymphoseek head and neck cancer clinical trial, NEO3-06, were discussed during a satellite symposium focused on Sentinel Lymph Node (SLN) biopsy in Head and Neck Cancer.
comments powered by